Jakobsen L, Christiansen EH, Freeman P, et al. - Given that target lesion failure is an issue with contemporary drug eluting stents, researchers sought to determine if the DTS (dual therapy sirolimus-eluting and CD34+ antibody coated Combo stent) is non-inferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population, in a large-scale randomized, multicenter, single-blind, two-arm, non-inferiority trial (SORT OUT X trial). Target lesion failure (TLF) was the primary endpoint, defined as a composite of cardiac death, myocardial infarction or target lesion revascularization within 12 months. In this study population, findings did not corroborate non-inferiority of DTS to the SES for TLF at 12 months. Superiority of SES to the DTS was evident mainly because the DTS was related to an elevated risk of target lesion revascularization. However, no significant differences in rates of death, cardiac death, and myocardial infarction at 12 months were found between the two stent groups.